Targeting myeloid MIF/CD74 axis in metastatic melanoma – mechanisms, prognostication and therapeutic opportunities
Bidragets beskrivning
Melanoma is the 5th most prevalent form of cancer in Finland, where the inhabitants are predominantly light-skinned. In the advanced stages, melanoma cells spread from the primary site (mostly the skin) via the bloodstream to distant organs. On that stage, surgery, radiotherapy and chemotherapy are less effective. One approach to treat metastatic melanoma is immunotherapy, which boosts the body's natural defences to eliminate the cancer cells. However, several melanoma patients develop mechanisms of resistance to this therapy. We discovered that melanoma cells may produce a factor called MIF, which turn off the body's natural defences, impairing the effectiveness of immunotherapy. In this project, we will validate MIF as a tool to select those patients that are eligible to respond to immunotherapy. For those that are not eligible, we will develop adjuvant strategies that neutralize MIF to restore the body's ability to kill cancer cells, unleashing the full power of immunotherapy.
Visa merStartår
2020
Slutår
2026
Beviljade finansiering
Andra beslut
358209
Akademiforskarens forskningskostnader(2023)
199 402 €
336530
Akademiforskarens forskningskostnader(2020)
300 022 €
Rollen i Finlands Akademis konsortium
Ledare
Finansiär
Finlands Akademi
Typ av finansiering
Akademiforskare
Utlysning
Övriga uppgifter
Finansieringsbeslutets nummer
330876
Vetenskapsområden
Biomedicinska vetenskaper
Forskningsområden
Biolääketieteet
Identifierade teman
cancer